Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

SEC Filing · EFFECT

TOURMALINE BIO INC

SEC Filing

Filed Nov 14, 2025Accepted Nov 16, 2025, 7:15 PM ESTCIK 1827506Accession 9999999995-25-003289
Share

Company context

Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that establish new standards of care for patients with life-altering inflammatory and immune diseases. Tourmaline’s lead asset is pacibekitug. For more information about Tourmaline and pacibekitug, please visit https://www.tourmalinebio.com or follow us on LinkedIn, X or Bluesky.

Historical securities (1)

Recent company filings

  1. EFFECT filingNov 14, 2025
  2. 15-12G filingNov 7, 2025
  3. 4 filingOct 28, 2025
  4. 4 filingOct 28, 2025
  5. 4 filingOct 28, 2025

As-filed source

Primary evidence